Beta2‐agonists vs placebo (single administration): Number of participants with an FEV1 fall > 10%
Beta2‐agonists probably leads to lower number of participants with an FEV1 fall > 10% compared with placebo (single administration) (moderate certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Beta2‐agonists vs placebo (single administration) Number of participants with an FEV1 fall > 10% · exercise‐induced asthma Beta2‐agonists probably leads to lower number of participants with an FEV1 fall > 10% compared with placebo (single administration) (moderate certainty). Beta₂‐agonists for exercise‐induced asthma (2013) · Cochrane Headline outcomes only | OR 0.08 [0.06, 0.13] | 19 studies · 773 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Beta₂‐agonists for exercise‐induced asthma 2013 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.